CannaPharmaRX, Inc. (CPMD)
OTCMKTS · Delayed Price · Currency is USD
0.0022
-0.0004 (-15.38%)
Aug 1, 2025, 11:20 AM EDT
Verve Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Cash & Equivalents | 0 | 0 | 0 | 0 | 0.03 | 0.33 | Upgrade |
Cash & Short-Term Investments | 0 | 0 | 0 | 0 | 0.03 | 0.33 | Upgrade |
Cash Growth | -90.01% | 231.69% | -71.95% | -91.66% | -91.71% | 21552.81% | Upgrade |
Accounts Receivable | 0.26 | 0 | - | - | - | - | Upgrade |
Other Receivables | 0.02 | 0.02 | 0.06 | 0.02 | 0 | 0 | Upgrade |
Receivables | 0.28 | 0.02 | 0.06 | 0.02 | 0 | 0 | Upgrade |
Inventory | 0.95 | 1 | 1.13 | - | - | - | Upgrade |
Prepaid Expenses | - | - | - | 0.07 | - | 0.13 | Upgrade |
Other Current Assets | - | - | - | 0.01 | - | - | Upgrade |
Total Current Assets | 1.24 | 1.02 | 1.2 | 0.1 | 0.03 | 0.47 | Upgrade |
Property, Plant & Equipment | 5.48 | 5.3 | 6.03 | 6.16 | 0.01 | 1.57 | Upgrade |
Long-Term Investments | 4.52 | 4.52 | 4.52 | 0.08 | 0.08 | 6.71 | Upgrade |
Total Assets | 11.23 | 10.84 | 11.75 | 6.34 | 0.11 | 8.75 | Upgrade |
Accounts Payable | 5.07 | 4.78 | 4.93 | 6.92 | 3.13 | 3.58 | Upgrade |
Accrued Expenses | 7.36 | 2.5 | 0.52 | 0.3 | 0.19 | 0.1 | Upgrade |
Short-Term Debt | 10.66 | 4.47 | 6.68 | 1.22 | 0.8 | 1.27 | Upgrade |
Current Portion of Long-Term Debt | 0.3 | 3.97 | 0.33 | 7.72 | 8.22 | 8.73 | Upgrade |
Current Portion of Leases | 0.95 | 0.73 | 0.75 | 0.26 | - | - | Upgrade |
Other Current Liabilities | 2.48 | 9.31 | 5.51 | 1.93 | 0.7 | 3.87 | Upgrade |
Total Current Liabilities | 26.89 | 25.75 | 18.73 | 18.35 | 13.04 | 17.55 | Upgrade |
Long-Term Leases | 4.85 | 4.89 | 5.17 | 5.33 | - | - | Upgrade |
Other Long-Term Liabilities | - | - | - | - | -0 | - | Upgrade |
Total Liabilities | 31.74 | 30.65 | 23.9 | 23.68 | 13.04 | 17.55 | Upgrade |
Common Stock | 0.07 | 0.07 | 0.04 | 0.03 | 0.01 | 0 | Upgrade |
Additional Paid-In Capital | 80.12 | 80.12 | 76.48 | 74.8 | 73.06 | 68.34 | Upgrade |
Retained Earnings | -101.87 | -101.18 | -91.28 | -94.97 | -86.16 | -77.33 | Upgrade |
Treasury Stock | - | - | - | -0 | -0 | -0 | Upgrade |
Comprehensive Income & Other | 0.55 | 0.56 | -0.03 | 0.24 | -0.37 | -0.35 | Upgrade |
Total Common Equity | -21.14 | -20.44 | -14.79 | -19.9 | -13.47 | -9.34 | Upgrade |
Shareholders' Equity | -20.51 | -19.81 | -12.15 | -17.34 | -12.93 | -8.8 | Upgrade |
Total Liabilities & Equity | 11.23 | 10.84 | 11.75 | 6.34 | 0.11 | 8.75 | Upgrade |
Total Debt | 16.76 | 14.06 | 12.94 | 14.52 | 9.02 | 10 | Upgrade |
Net Cash (Debt) | -16.76 | -14.06 | -12.93 | -14.52 | -8.99 | -9.67 | Upgrade |
Net Cash Per Share | -0.02 | -0.02 | -0.04 | -0.07 | -0.12 | -0.24 | Upgrade |
Filing Date Shares Outstanding | 656.27 | 656.27 | 656.27 | 298.85 | 166.45 | 50.03 | Upgrade |
Total Common Shares Outstanding | 656.27 | 656.27 | 434.52 | 273.99 | 125.38 | 46.85 | Upgrade |
Working Capital | -25.66 | -24.73 | -17.53 | -18.25 | -13.01 | -17.08 | Upgrade |
Book Value Per Share | -0.03 | -0.03 | -0.03 | -0.07 | -0.11 | -0.20 | Upgrade |
Tangible Book Value | -21.14 | -20.44 | -14.79 | -19.9 | -13.47 | -9.34 | Upgrade |
Tangible Book Value Per Share | -0.03 | -0.03 | -0.03 | -0.07 | -0.11 | -0.20 | Upgrade |
Machinery | 0.21 | 0.21 | 0.21 | 0.13 | 0.01 | 0 | Upgrade |
Construction In Progress | - | - | - | - | - | 1.57 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.